Presented by Professor Reinhard Dummer, Professor of the University of Zurich and Vice-Chairman of the Department of Dermatology in the University Hospital of Zürich, Switzerland, this webinar reviews late breaking news, key takeaways, clinical data and other updates presented at the European Society for Medical Oncology (ESMO) Virtual Congress Annual Meeting September-October 2020. Dr. Dummer shares his key insights into what the landscape of melanoma and non-melanoma skin cancer treatment looks like for the near future. Watch until the end to see Dr. Dummer and Kathy Barnard discuss hope and survivorship in melanoma skin cancer.
Prof. Reinhard Dummer, MD
Vice-Chairman, Department of Dermatology
University Hospital of Zürich, Switzerland
Professor Reinhard Dummer is Professor of the University of Zurich and Vice-Chairman of the Department of Dermatology in the University Hospital of Zürich, Switzerland and is a key thought leader in worldwide cutaneous oncology. Currently he is heading of the Skin Cancer Unit and the Clinical Trial Unit of the Department of Dermatology. Professor Dummer began his medical education in haematology and oncology before successfully completing his dermatology residency in Würzburg, Germany, and Zürich in 1992.
He is Board Certified in allergology, clinical immunology, dermatology and dermatopathology.
Professor Dummer’s principal research interests are molecular biology, immunology and immunotherapy of cutaneous malignancies, including cutaneous lymphomas and melanomas. He has published more than 741 papers with a cumulative impact factor of more than 6372. He w as past-president of the Melanoma Project Group of the Swiss Institute for Applied Cancer Research since 1999 -2016, is a member of German National Academy of Sciences (Leopoldina) and is past board member of the Society for Melanoma Research and past President of the International Society for Cutaneous Lymphomas.
He is a founding and board member of the European Association of Dermato-Oncology (EADO), ESMO, URPP and past President of the European Society for Dermatological Research (ESDR).
In the last 20 years, he has developed a leading skin cancer center. This center offers best medical care, a network of clinical trials reaching from phase I to phase III. His contributions are acknowledge in many publications in outstanding journals such as New England Journal of Medicine, Lancet, Lancet Oncology, Press etc. Locally he is intensify cooperation with basic research group at the University and the federal University (ETH). This has resulted in translation work improving our understanding of cutaneous malignancies.